0749 GMT - Revenue from Roche's Tecentriq drug is unlikely to significantly increase despite data showing that in combination with lurbinectedin, it prolongs the life of patients with small-cell lung cancer, Vontobel analyst Stefan Schneider writes. Tecentriq was already approved in 2019 for use in combination with chemotherapy, he writes. Data from Roche shows that the median progression-free survival time was 5.4 months for the combination versus 2.1 months in the Tecentriq-alone arm, he writes. While this is an improvement, there is clearly room for more, he writes. Shares trade down 0.4% at 283.10 Swiss francs. (adam.whittaker@wsj.com)
(END) Dow Jones Newswires
June 03, 2025 03:51 ET (07:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.